. 2019 Dec; 14(2):103-110.
doi: 10.1159/000499931.

St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment

Marija Balic 1 Christoph Thomssen 2 Rachel Würstlein 3 Michael Gnant 4 Nadia Harbeck 3 
  • PMID: 31798382
  •     13 References
  •     37 citations


This year, the St. Gallen Consensus Conference on early breast cancer treatment standards took place for the third time in Vienna, Austria, which is where the next conference will also take place (next date: March 17-20, 2021!). Once again, more than 3,000 participants from over 100 countries came together, and, overall, the 2019 St. Gallen/Vienna conference was a great success. After 3 days of reviews conducted by a global faculty concerning the most important evidence published in the last 2 years, the Consensus votes' challenge was to define the impact on routine everyday practice. This year, the conference's main theme was the optimization of early breast cancer therapies by assessment of the magnitude of benefit, aiming at further refinement when compared to de-escalation and escalation, which were mainly the topic of the 2017 conference. Patient empowerment and the importance of shared decision-making were particularly emphasized. The traditional panel votes were moderated by Eric Winer from Harvard, and for the most part, they managed to clarify most of the critical questions. This brief report by Editors of Breast Care summarizes the results of the 2019 international panel votes with respect to locoregional and systemic treatment as a quick news update for our readers, but it expressly does not intend to replace the official St. Gallen Consensus publication that will follow shortly in Annals of Oncology.

Keywords: Adjuvant treatment; Axillary dissection; Bisphosphonates; Breast surgery; Chemotherapy; Denosumab; Early breast cancer; Endocrine therapy; Neoadjuvant systemic therapy; Radiotherapy; Sentinel node; Targeted therapy.

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
Sukhbinder Dhesy-Thind, Glenn G Fletcher, +9 authors, Catherine H Van Poznak.
J Clin Oncol, 2017 Jun 16; 35(18). PMID: 28618241
Highly Cited. Systematic Review.
St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment.
Michael Gnant, Nadia Harbeck, Christoph Thomssen.
Breast Care (Basel), 2017 Jun 01; 12(2). PMID: 28559767    Free PMC article.
Highly Cited. Review.
Adjuvant ovarian suppression in premenopausal breast cancer.
Prudence A Francis, Meredith M Regan, +28 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Dec 17; 372(5). PMID: 25495490    Free PMC article.
Highly Cited.
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Michael Gnant, Georg Pfeiler, +24 authors, Austrian Breast and Colorectal Cancer Study Group.
Lancet, 2015 Jun 05; 386(9992). PMID: 26040499
Highly Cited.
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Fatima Cardoso, Laura J van't Veer, +32 authors, MINDACT Investigators.
N Engl J Med, 2016 Aug 25; 375(8). PMID: 27557300
Highly Cited.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Olivia Pagani, Meredith M Regan, +32 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Jun 03; 371(2). PMID: 24881463    Free PMC article.
Highly Cited.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Miguel Martin, Frankie A Holmes, +32 authors, ExteNET Study Group.
Lancet Oncol, 2017 Nov 18; 18(12). PMID: 29146401
Highly Cited.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
Gunter von Minckwitz, Marion Procter, +16 authors, APHINITY Steering Committee and Investigators.
N Engl J Med, 2017 Jun 06; 377(2). PMID: 28581356    Free PMC article.
Highly Cited.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Gunter von Minckwitz, Chiun-Sheng Huang, +27 authors, KATHERINE Investigators.
N Engl J Med, 2018 Dec 06; 380(7). PMID: 30516102
Highly Cited.
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Gnant, Georg Pfeiler, +17 authors, Austrian Breast and Colorectal Cancer Study Group.
Lancet Oncol, 2019 Feb 24; 20(3). PMID: 30795951
Highly Cited.
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2015 Jul 28; 386(10001). PMID: 26211824
Highly Cited.
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
Ulrike Nitz, Oleg Gluz, +18 authors, West German Study Group PlanB Investigators.
J Clin Oncol, 2019 Feb 21; 37(10). PMID: 30785826
High FUT3 expression is a marker of lower overall survival of breast cancer patients.
Jessica Catarine Frutuoso do Nascimento, Eduardo Isidoro Carneiro Beltrão, Cíntia Renata Costa Rocha.
Glycoconj J, 2020 Feb 18; 37(2). PMID: 32062822
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.
Mohamed Amgad, Elisabeth Specht Stovgaard, +66 authors, International Immuno-Oncology Biomarker Working Group.
NPJ Breast Cancer, 2020 May 16; 6. PMID: 32411818    Free PMC article.
Empowering patients in decision-making in radiation oncology - can we do better?
Michelle Leech, Matthew S Katz, +2 authors, Sandra Turner.
Mol Oncol, 2020 Mar 22; 14(7). PMID: 32198967    Free PMC article.
Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter?
Adam Brufsky, Aju Mathew.
J Natl Cancer Inst, 2019 Nov 07; 112(7). PMID: 31693134    Free PMC article.
Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database.
Zeina A Nahleh, Elizabeth B Elimimian, +3 authors, Cassann N Blake.
Breast Cancer (Auckl), 2020 Aug 22; 14. PMID: 32821110    Free PMC article.
Caring about bone-modifying agents (BMAs) in women with early-stage breast cancer.
Charles L Shapiro.
Ann Transl Med, 2020 Sep 22; 8(16). PMID: 32953838    Free PMC article.
Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer.
Qing Li, Jiani Wang, +9 authors, Binghe Xu.
Chin J Cancer Res, 2020 Sep 24; 32(4). PMID: 32963461    Free PMC article.
Genomic Signatures in Luminal Breast Cancer.
Julian Puppe, Tabea Seifert, +3 authors, Wolfram Malter.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982645    Free PMC article.
The use of moderately hypofractionated post-operative radiation therapy for breast cancer in clinical practice: A critical review.
Gustavo Nader Marta, Charlotte Coles, +10 authors, Philip Poortmans.
Crit Rev Oncol Hematol, 2020 Oct 23; 156. PMID: 33091800    Free PMC article.
Breast cancers, mammary stem cells, and cancer stem cells, characteristics, and hypotheses.
Sebastien Taurin, Haifa Alkhalifa.
Neoplasia, 2020 Nov 04; 22(12). PMID: 33142233    Free PMC article.
Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen.
Young-Jin Lee, Zhen-Yu Wu, +10 authors, BeomSeok Ko.
J Breast Cancer, 2020 Nov 07; 23(5). PMID: 33154830    Free PMC article.
Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments.
Charles L Shapiro.
Cancers (Basel), 2020 Oct 30; 12(11). PMID: 33114141    Free PMC article.
The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer.
Lei Zhang, Ru Tang, +4 authors, Zhen-Yu He.
BMC Cancer, 2020 Nov 27; 20(1). PMID: 33238939    Free PMC article.
Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems.
Patrícia de Faria Lainetti, Antonio Fernando Leis-Filho, +2 authors, Carlos Eduardo Fonseca-Alves.
Pharmaceutics, 2020 Dec 16; 12(12). PMID: 33316872    Free PMC article.
Prognostic and predictive parameters in breast pathology: a pathologist's primer.
Kimberly H Allison.
Mod Pathol, 2020 Nov 07; 34(Suppl 1). PMID: 33154551
Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria.
Jamal Zekri, Meteb Al-Foheidi, +2 authors, Ayman Rasmy.
Breast Care (Basel), 2021 Jan 16; 15(6). PMID: 33447239    Free PMC article.
Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation.
Sharon McGee, Mashari AlZahrani, +11 authors, Mark Clemons.
J Bone Oncol, 2021 Mar 09; 27. PMID: 33680749    Free PMC article.
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
Albert Gris-Oliver, Yasir H Ibrahim, +21 authors, Violeta Serra.
Br J Cancer, 2021 Mar 17; 124(9). PMID: 33723394    Free PMC article.
Real-World Outcomes Among Older Mexican Women with Breast Cancer Treated with Neoadjuvant Chemotherapy.
Paula Cabrera-Galeana, Enrique Soto-Perez-de-Celis, +7 authors, Juan Enrique Bargallo-Rocha.
Oncologist, 2020 Apr 11; 25(12). PMID: 32275801    Free PMC article.
Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey.
Sharon McGee, Mashari Alzahrani, +7 authors, Mark Clemons.
Breast Cancer Res Treat, 2021 Mar 24; 187(2). PMID: 33755864    Free PMC article.
Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer.
Ipshita Prakash, Samantha M Thomas, +4 authors, Oluwadamilola M Fayanju.
Breast Cancer Res Treat, 2020 Nov 19; 186(2). PMID: 33206290    Free PMC article.
From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors.
Leonor Vasconcelos de Matos, Leonor Fernandes, +9 authors, Ana Martins.
Curr Oncol, 2021 Mar 04; 28(2). PMID: 33652975    Free PMC article.
2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina.
Semir Bešlija, Zdenka Gojković, +33 authors, Rajna Stanušić.
Bosn J Basic Med Sci, 2020 May 18; 21(2). PMID: 32415816    Free PMC article.
Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.
Milos Holanek, Iveta Selingerova, +10 authors, Alexandr Poprach.
Cancers (Basel), 2021 Apr 04; 13(7). PMID: 33808149    Free PMC article.
A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Junichi Kurebayashi, Eiichi Shiba, +6 authors, Yasuo Ohashi.
Breast Cancer, 2021 Feb 28; 28(3). PMID: 33638810    Free PMC article.
Utility of post mastectomy radiotherapy among patients with T1/ T2 N1 disease: A retrospective cohort study.
Lubna M Vohra, Rufina Soomro, +2 authors, Nargis Khan.
Ann Med Surg (Lond), 2021 May 06; 65. PMID: 33948170    Free PMC article.
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.
Elizabeth M Salvo, Abril Oliva Ramirez, +4 authors, Imtiaz A Samjoo.
Breast, 2021 Mar 08; 57. PMID: 33677313    Free PMC article.
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches.
Jason Schick, Raquel P Ritchie, Carolina Restini.
Breast Cancer (Auckl), 2021 May 18; 15. PMID: 33994789    Free PMC article.
Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer.
Zhen-Yu Wu, Young-Jin Lee, +10 authors, BeomSeok Ko.
Front Oncol, 2021 May 18; 11. PMID: 33996592    Free PMC article.
St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer.
Christoph Thomssen, Marija Balic, Nadia Harbeck, Michael Gnant.
Breast Care (Basel), 2021 May 19; 16(2). PMID: 34002112    Free PMC article.
Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis.
M G Davey, É J Ryan, +3 authors, M J Kerin.
Breast, 2021 May 23; 58. PMID: 34022714    Free PMC article.
Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.
Hesham Elghazaly, Hope S Rugo, +36 authors, Hagar Elghazawy.
Cancers (Basel), 2021 Jun 03; 13(9). PMID: 34066769    Free PMC article.
The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials.
Carlos Ortega Expósito, Catalina Falo, +22 authors, Amparo García Tejedor.
Breast Cancer Res Treat, 2021 Jun 06; 189(1). PMID: 34089119
The clinical and molecular significance associated with STING signaling in breast cancer.
Eileen E Parkes, Matthew P Humphries, +13 authors, Niamh E Buckley.
NPJ Breast Cancer, 2021 Jun 27; 7(1). PMID: 34172750    Free PMC article.
Automated Quantification of sTIL Density with H&E-Based Digital Image Analysis Has Prognostic Potential in Triple-Negative Breast Cancers.
Jeppe Thagaard, Elisabeth Specht Stovgaard, +10 authors, Eva Balslev.
Cancers (Basel), 2021 Jul 03; 13(12). PMID: 34207414    Free PMC article.
The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa.
Ettienne J Myburgh, Josephus J de Jager, +3 authors, Hermanus de Klerk.
Breast, 2021 Jul 04; 59. PMID: 34217105    Free PMC article.
Theory, methods, and operational results of the Young Women's Health History Study: a study of young-onset breast cancer incidence in Black and White women.
Ellen M Velie, Lydia R Marcus, +15 authors, Kendra Schwartz.
Cancer Causes Control, 2021 Jul 23;. PMID: 34292440